Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Accumulated Expenses (2023 - 2025)

Bioharvest Sciences has reported Accumulated Expenses over the past 3 years, most recently at $386000.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 3.74% year-over-year to $386000.0; the TTM value through Dec 2025 reached $386000.0, down 3.74%, while the annual FY2025 figure was $386000.0, 3.74% down from the prior year.
  • Accumulated Expenses was $386000.0 for Q4 2025 at Bioharvest Sciences, down from $946000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $946000.0 in Q3 2025 and bottomed at $197000.0 in Q3 2024.
  • The 3-year median for Accumulated Expenses is $401000.0 (2024), against an average of $422777.8.
  • The widest YoY moves for Accumulated Expenses: up 380.2% in 2025, down 45.89% in 2025.
  • Over 3 years, Accumulated Expenses stood at $458000.0 in 2023, then dropped by 12.45% to $401000.0 in 2024, then dropped by 3.74% to $386000.0 in 2025.
  • The last three reported values for Accumulated Expenses were $386000.0 (Q4 2025), $946000.0 (Q3 2025), and $463000.0 (Q2 2025) per Business Quant data.